Executive summary. The route of administration changes onset, exposure, duration, dose precision and risk. Medical cannabis should not be discussed as though flower, oils, capsules and sprays are interchangeable. Formulation, device performance and patient capability all influence the delivered dose.
Oral administration
Capsules, oils and solutions offer measured dosing but undergo gastrointestinal absorption and first-pass metabolism. Exposure can vary and may be influenced by food. Onset is slower than inhalation and effects may last longer. Dose-measurement devices and formulation uniformity are important.
Oral administration’s variable and often low bioavailability, driven by extensive first-pass metabolism, means dose titration guidance for oral cannabis products should be more conservative than for other routes with faster, more predictable onset.
Oromucosal administration
Oromucosal sprays aim to deliver through the oral mucosa and through swallowed fractions. Pump performance, priming, delivered-dose uniformity and in-use stability are critical. Patient technique can influence exposure.
Oromucosal administration avoids first-pass metabolism and offers more predictable onset than oral dosing, but achieving consistent absorption depends heavily on correct administration technique, which should be addressed directly in patient counselling.
Inhaled administration
Vaporised flower or formulated inhalation products can provide rapid onset. Combustion introduces additional toxicants and is generally not a pharmaceutical delivery ideal. Vapour devices require control of temperature, emissions, dose delivery and cleaning.
Inhaled administration provides the fastest onset and most dose-titratable route, which is clinically valuable but also carries the greatest risk of acute psychoactive effect if patients are not adequately counselled on starting dose.
Topical and transdermal administration
Topical products primarily act locally unless a transdermal system is specifically designed for systemic delivery. Skin permeability, excipients, dose area and adhesion matter. Claims should not assume systemic exposure from a conventional topical formulation.
Topical and transdermal administration is generally used for localised effect rather than systemic therapeutic levels, and marketing claims should not imply systemic efficacy without supporting pharmacokinetic evidence for that specific formulation.
Other investigational routes
Nasal, pulmonary, sublingual, rectal and parenteral systems have been explored. These routes require dosage-form-specific evidence and may create sterility, device or bioavailability challenges.
Other investigational routes remain outside standard clinical practice and should be treated as research-stage delivery mechanisms rather than options with an established safety and efficacy record.
Patient and clinical considerations
Age, swallowing ability, pulmonary disease, cognitive impairment, need for rapid onset and risk of dosing error should influence route selection. The most convenient format is not always the safest or most predictable.
Route selection should be guided primarily by the clinical indication and patient population — a route chosen for manufacturing convenience rather than clinical appropriateness increases the risk of poor treatment adherence.
Quality and regulatory implications
Each route creates its own critical quality attributes. A flower specification cannot simply be transferred to a capsule or spray. Product development should link route, formulation, performance test and clinical instructions.
Regulatory and quality requirements differ meaningfully by route — an inhalation product’s microbiological and impurity specifications are not interchangeable with those appropriate for an oral or topical formulation of the same cannabinoid.
Practical reference table
| Route | Typical onset | Main advantage | Main quality risk |
|---|---|---|---|
| Oral | Slower | Measured dose and duration | Variable absorption and food effect |
| Oromucosal | Intermediate | Metered portable delivery | Pump and technique variability |
| Inhaled/vaporised | Rapid | Fast titration | Device emissions and dose variability |
| Topical | Local | Targeted use | Uncertain penetration and uniformity |
| Transdermal | Slow sustained | Potential steady delivery | Adhesion and permeation |
| Parenteral | Immediate | Controlled systemic delivery | Sterility and pyrogen risk |
Decision and implementation path
Common implementation mistakes
Common mistakes include choosing a country because cultivation appears attractive without confirming product access; assuming that GMP certification resolves controlled-drug permissions; using broad cannabis terminology where the active substance is not clearly defined; and relying on commercial claims that exceed the available evidence. A second recurring weakness is treating laboratories, logistics providers or cultivators as external to the pharmaceutical quality system. Outsourced work remains part of the regulated supply chain and requires qualification, agreements, performance review and change notification.
Frequently asked questions
Which route works fastest?
Inhaled routes generally have the fastest onset.
Are cannabis oils absorbed consistently?
Exposure can vary between patients and may be influenced by food and formulation.
Is a topical product the same as a transdermal product?
No. Transdermal systems are designed to deliver through the skin into systemic circulation.
Why must spray devices be tested?
The pump determines how much product is delivered per actuation.
Is smoking a pharmaceutical dosage form?
Combustion is difficult to control and introduces harmful by-products; regulated products generally favour more controlled routes.
Primary references and guidance
- European Pharmacopoeia dosage-form chapters
- ICH Q8(R2)
- ICH Q1A(R2)
- EU GMP Part I, Chapters 5 and 6
- EMA pharmaceutical-development guidance
- EMA product information for authorised cannabinoid medicines
- Relevant clinical pharmacokinetic literature
Confirm the current effective version and national applicability before operational, medical or regulatory use.